ClinicalTrials.gg
RecruitingNCT05873543SHCR-HFUpdated Nov 18, 2026

The Effect of a Smartphone-assisted Hybrid Cardiac Rehabilitation Program in Patients With Heart Failure.

An interventional study of smartphone-assisted hybrid cardiac rehabilitation (SHCR) in Heart Failure, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Heart Failure by National Taiwan University Hospital — 7 open to participants now, 9 under way, 1 of them phase 3. Heart Failure · National Taiwan University Hospital.

Planned enrollment
2nd of 15
150 · median 60
Started
2024
with 1 other
No phase
10 of 25
4 open now
Registered
15th of 25
by date

Among the 25 studies in Heart Failure by National Taiwan University Hospital, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, and was the 15th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 25 studies in Heart Failure by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Heart Failure by National Taiwan University Hospital, or all of them as a file.
02

Study summary

The aim of this randomized controlled trial is to compare the impact of a case manager-led smartphone-assisted hybrid cardiac rehabilitation program with usual care in patients with HF. Participants will undergo a 12-week program led by a case manager and assisted by a smartphone. The study aims to answer two main questions:

  1. Is the novel cardiac rehabilitation model feasible for patients with HF?
  2. Does the intervention group show a significant improvement in exercise capacity and adherence compared to the usual care group?
03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • cardiac rehabilitation
  • heart failure
  • eHealth
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with heart failure between the ages of 18 and 80 years old.
  • (New York Heart Association) functional classification of 1 to 3.
  • Patients must be in a stable condition and under outpatient follow-up.

Exclusion criteria

Exclusion Criteria:

  • Patients who have for exercise according to the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription.
  • Patients who are unable to complete cardiopulmonary exercise testing.
  • Patients who are unable to follow verbal instructions.
  • Patients who are unable to walk independently or pedal a stationary bicycle.
  • Patients who are unable to use communication app on a smartphone.
  • Patients who already engage in physical activity exceeding the recommended moderate intensity of 150 minutes per week or are currently participating in cardiac rehabilitation.
  • Patients who do not provide consent to participate in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    smartphone-assisted hybrid cardiac rehabilitation (SHCR)

    Participants receive a 12-wk case manager-led smartphone-assisted hybrid cardiac rehabilitation with follow-up at 12 week and 6 months.

    Other: smartphone-assisted hybrid cardiac rehabilitation (SHCR)

  • No intervention
    Usual care

    Participants receive usual care including general education and exercise suggestion.

Interventions

  • Othersmartphone-assisted hybrid cardiac rehabilitation (SHCR)

    The 12-week case manager-led SHCR program includes: * Customized exercise prescriptions following ACSM's heart failure guidelines. * A hybrid program combining in-person sessions, home self-exercise, and videoconferencing for exercise coaching(optional), supported by a smartphone app. * Case managers instruct patients on a communication app for weekly follow-ups, health education messages, exercise reminders, and progress tracking, including metrics like blood pressure, heart rate, weight, and symptoms.

06

What researchers measure

Primary outcomes

  1. Change of peak oxygen uptake

    Peak oxygen uptake will be assessed using cardiopulmonary exercise test before intervention, at 12 weeks (post-intervention), and at 6 months.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  2. Change of 6 minute walking test

    6 minute walking test will be performed before intervention, at 12 weeks (post-intervention), and at 6 months.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

Secondary outcomes

  1. Adherence to prescribed exercise

    We will evaluate the percentage of completed prescribed exercises at 12 weeks.

    Time frame: 12 weeks(post-intervention)

  2. Evaluation of Quality of life

    The investigators will assess the change in 36-Item Short Form Survey(SF-36).

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  3. Depression

    The investigators will assess the change in Patient Health Questionnaire (PHQ-9). The PHQ-9 score ranges from 0-27. Higher scores indicate worsen symptoms.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  4. Anxiety

    The investigators will assess the change in Generalized Anxiety Disorder scale (GAD-7). The GAD-7 score ranges 0-21. Higher scores indicate worsen symptoms.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  5. Evaluation of physical activity

    The investigators will assess the change in physical activity using International Physical Activity Questionnaire(IPAQ) Taiwan version.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  6. Evaluation of grip strength

    The grip strength will be measured using a grip goniometer with the participants seated and the elbow flexed at 90 degrees.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  7. Evaluation of frailty

    The investigators will evaluate the change in the Clinical Frailty Scale, which ranges from 1 to 9. Higher scores represent greater illness.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  8. Blood test: Total cholesterol

    The Total cholesterol will be tested in the laboratory.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  9. Blood test: LDL

    The LDL will be tested in the laboratory.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  10. Blood test: HDL

    The HDL will be tested in the laboratory.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  11. Blood test: Triglyceride

    The Triglyceride will be tested in the laboratory.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

  12. Blood test: NT-proBNP

    The NT-proBNP will be tested in the laboratory.

    Time frame: at baseline, 12 weeks(post-intervention), and 6 months.

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2028, 58 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 58 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2023
First posted
May 24, 2023
StartActual
Jan 26, 2024
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05873543
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Jan 26, 2024
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Hung-Jui Chuang, MD
Contact
rexintwo@gmail.com
00886-2-23123456 ext. 67034
Hung-Jui Chuang, MD
principal investigator · Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion